188 related articles for article (PubMed ID: 37462205)
21. Combined deep penetrating nevi of the conjunctiva are relatively common lesions characterised by BRAFV600E mutation and activation of the beta catenin pathway: a clinicopathological analysis of 34 lesions.
Šekoranja D; Vergot K; Hawlina G; Pižem J
Br J Ophthalmol; 2020 Jul; 104(7):1016-1021. PubMed ID: 31558492
[TBL] [Abstract][Full Text] [Related]
22. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi.
Lohman ME; Steen AJ; Grekin RC; North JP
J Cutan Pathol; 2021 Jul; 48(7):856-862. PubMed ID: 33433032
[TBL] [Abstract][Full Text] [Related]
23. Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Magro CM; Abraham RM; Guo R; Li S; Wang X; Proper S; Crowson AN; Mihm M
Eur J Dermatol; 2014; 24(5):594-602. PubMed ID: 25118781
[TBL] [Abstract][Full Text] [Related]
24. The deep penetrating nevus.
Strazzula L; Senna MM; Yasuda M; Belazarian L
J Am Acad Dermatol; 2014 Dec; 71(6):1234-40. PubMed ID: 25175710
[TBL] [Abstract][Full Text] [Related]
25. Pitfalls of PRAME Immunohistochemistry in a Large Series of Melanocytic and Nonmelanocytic Lesions With Literature Review.
Turner N; Ko CJ; McNiff JM; Galan A
Am J Dermatopathol; 2024 Jan; 46(1):21-30. PubMed ID: 37982498
[TBL] [Abstract][Full Text] [Related]
26. Desmoplastic (sclerotic) nevus: an underrecognized entity that resembles dermatofibroma and desmoplastic melanoma.
Harris GR; Shea CR; Horenstein MG; Reed JA; Burchette JL; Prieto VG
Am J Surg Pathol; 1999 Jul; 23(7):786-94. PubMed ID: 10403301
[TBL] [Abstract][Full Text] [Related]
27. p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma.
Oaxaca G; Billings SD; Ko JS
J Cutan Pathol; 2020 Sep; 47(9):815-823. PubMed ID: 32330325
[TBL] [Abstract][Full Text] [Related]
28. Blue nevi and related lesions: a review highlighting atypical and newly described variants, distinguishing features and diagnostic pitfalls.
Murali R; McCarthy SW; Scolyer RA
Adv Anat Pathol; 2009 Nov; 16(6):365-82. PubMed ID: 19851128
[TBL] [Abstract][Full Text] [Related]
29. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
30. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi.
Hu J; Cai X; Lv JJ; Wan XC; Zeng XY; Feng ML; Dai B; Kong YY
Hum Pathol; 2022 Feb; 120():9-17. PubMed ID: 34800527
[TBL] [Abstract][Full Text] [Related]
31. PRAME immunohistochemistry is useful in differentiating oral melanomas from nevi and melanotic macules.
Schmitt TA; Lee JC; Martinka M; Ko KYC
J Cutan Pathol; 2023 Mar; 50(3):275-278. PubMed ID: 36398487
[TBL] [Abstract][Full Text] [Related]
32. Blue lesions.
Longo C; Scope A; Lallas A; Zalaudek I; Moscarella E; Gardini S; Argenziano G; Pellacani G
Dermatol Clin; 2013 Oct; 31(4):637-47, ix. PubMed ID: 24075551
[TBL] [Abstract][Full Text] [Related]
33. ALK Rearrangements Are Infrequent in Cellular Blue Nevus and Deep Penetrating Nevus.
Dunn ALJ; Gardner JM; Kaley JR; Bellamy W; Shalin SC
Am J Dermatopathol; 2018 Jul; 40(7):469-478. PubMed ID: 29923908
[TBL] [Abstract][Full Text] [Related]
34. Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization.
Pouryazdanparast P; Newman M; Mafee M; Haghighat Z; Guitart J; Gerami P
Am J Surg Pathol; 2009 Sep; 33(9):1396-400. PubMed ID: 19606012
[TBL] [Abstract][Full Text] [Related]
35. PRAME Expression in Melanocytic Proliferations in Special Sites.
Maniaci JL; Raghavan SS
Cutis; 2024 Jan; 113(1):43-47. PubMed ID: 38478941
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of PRAME in distinguishing proliferative nodules from melanoma in giant congenital melanocytic nevi.
Gill P; Prieto VG; Austin MT; Giubellino A; Torres-Cabala CA
J Cutan Pathol; 2021 Nov; 48(11):1410-1415. PubMed ID: 34164835
[TBL] [Abstract][Full Text] [Related]
37. SF3B1 and BAP1 mutations in blue nevus-like melanoma.
Griewank KG; Müller H; Jackett LA; Emberger M; Möller I; van de Nes JA; Zimmer L; Livingstone E; Wiesner T; Scholz SL; Cosgarea I; Sucker A; Schimming T; Hillen U; Schilling B; Paschen A; Reis H; Mentzel T; Kutzner H; Rütten A; Murali R; Scolyer RA; Schadendorf D
Mod Pathol; 2017 Jul; 30(7):928-939. PubMed ID: 28409567
[TBL] [Abstract][Full Text] [Related]
38. Comparative Analysis of PRAME Expression in 127 Acral and Nail Melanocytic Lesions.
Santandrea G; Valli R; Zanetti E; Ragazzi M; Pampena R; Longo C; Lai M; Piana S; Cesinaro AM
Am J Surg Pathol; 2022 May; 46(5):579-590. PubMed ID: 35275883
[TBL] [Abstract][Full Text] [Related]
39. Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.
Koch EAT; Erdmann M; Berking C; Kiesewetter F; Kramer R; Schliep S; Heppt MV
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047361
[TBL] [Abstract][Full Text] [Related]
40. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
